tbc-11251 has been researched along with uric acid in 2 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (uric acid) | Trials (uric acid) | Recent Studies (post-2010) (uric acid) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 27,980 | 1,717 | 9,982 |
| Protein | Taxonomy | tbc-11251 (IC50) | uric acid (IC50) |
|---|---|---|---|
| Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 300 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaun, N; Goddard, J; Johnston, NR; Webb, DJ | 1 |
| Benza, RL; Dhaun, N; Hwang, LJ; Liu, X; Naeije, R; Teal, S; Vachiery, JL; Webb, DJ | 1 |
2 trial(s) available for tbc-11251 and uric acid
| Article | Year |
|---|---|
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
Topics: Cross-Over Studies; Double-Blind Method; Endothelin A Receptor Antagonists; Hypertension; Hyperuricemia; Isoxazoles; Kidney Failure, Chronic; Thiophenes; Treatment Outcome; Uric Acid | 2011 |
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bosentan; Child; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Prospective Studies; Sulfonamides; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; United States; Uric Acid; Young Adult | 2014 |